For years, red light therapy (or more precisely, photobiomodulation) sat just outside the center of medicine. Not rejected. Not ignored. But never fully adopted.
That’s changing.
The question is no longer whether light can influence biology. It can. And in the case of the eye, the evidence is increasingly compelling.
This is not a new idea
I’ve covered this in detail in earlier issues, breaking down:
• how photobiomodulation improves retinal function
• how it counteracts age-related vision decline
• and why the retina—one of the most energy-hungry tissues in the body—responds so well to mitochondrial stimulation
Those pieces established the foundation:
✅ The mechanism is not speculative (it targets cytochrome c oxidase in mitochondria)
✅ The biological response is measurable
✅ The outcomes are real
But that groundwork points to a more important question.
The wrong question has been asked
Public discussion still often asks: “Can red light therapy help macular degeneration?”
That question has a positive answer. Multiple clinical trials—including those leading to the FDA’s recent authorization of the Valeda Light Delivery System—have shown consistent signals of:
• improved visual acuity (typically 5+ ETDRS letters, or about one line on an eye chart)
• reduction or stabilization of drusen volume
• slower progression to geographic atrophy in dry AMD
These align with the expected biology: better mitochondrial function → more cellular energy → reduced inflammation and improved retinal health.
So the real question is no longer “if,” but “how do we amplify and sustain the results?”
Why are the results still limited?
They are—and that’s important to acknowledge.
• Improvements are measurable, but often modest
• Benefits tend to fade without ongoing or repeated treatment
• Protocols vary widely across studies
• Patient responses are inconsistent
Photobiomodulation is working, but we’re still largely in the first generation of applications.
Look at how it’s currently used:
• Specific wavelength combinations (successful trials often use multi-wavelength: yellow 590 nm, red ~660 nm, and near-infrared ~850 nm, not just single ~670 nm)
• Fixed or intermittent treatment schedules (e.g., series of sessions repeated every few months)
• One-size-fits-most protocols
This is proof of concept, not optimization.
The missing layer: amplification
The logical next step is refinement and amplification. Key open questions include:
• What is the optimal combination, dosing, and frequency of wavelengths?
• Is treatment frequency too low to sustain long-term cellular changes?
• Would earlier intervention (before significant structural damage) yield dramatically better outcomes?
• Can results be enhanced by combining PBM with nutritional support (e.g., AREDS formulas), metabolic optimization, or lifestyle factors?
• Which patients respond best—and can we identify biomarkers for strong responders?
This is where the real work—and opportunity—begins.
Photobiomodulation sits between proof-of-concept and clinical maturity. We have enough evidence to take it seriously. But not enough refinement yet to unlock its full potential.
How far can we push the effect?
• Can modest gains become significant functional recovery?
• Can treatment be personalized?
• Can early, proactive intervention prevent structural damage altogether?
Until these questions receive rigorous answers, the story remains incomplete—not because the underlying science is weak, but because the application is still early.
What do you think? Have you tried or considered light-based therapies for eye health? Drop your thoughts in the comments or reply, I’d love to hear.